bioMérieux S.A. (BMXMF) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
P/E 18.16 means the share price is 18.16 times one year of earnings per share; the S&P 500 usually sits near 20-25. Market cap $10.2B is the value of all shares combined.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerbioMérieux S.A. (BMXMF) trades at $86.11. bioMérieux S.A. is a global leader in in vitro diagnostics, focusing on infectious disease diagnosis and microbiological testing. Market cap: $10.2B, Sector: Healthcare.
Price as of Sep 11, 2026 · Last analyzed: Mar 15, 2026Analyst Coverage for BMXMF: BMXMF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates BMXMF against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
BMXMF: 2/2 scored disciplines lean bullish. Dominant signal: Ken Griffin bullish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
bioMérieux S.A. (BMXMF) Healthcare & Pipeline Overview
bioMérieux S.A. develops and produces in vitro diagnostic solutions for infectious diseases, cardiovascular pathologies, and cancers. Serving clinical and industrial sectors globally, the company leverages its diagnostic systems and microbiological testing capabilities. As a subsidiary of Institut Mérieux SA, bioMérieux focuses on advancing healthcare through innovative diagnostic solutions.
What Is the Investment Thesis for BMXMF?
With a market capitalization of $10.2B and a healthy profit margin of 9.8%, the company demonstrates financial stability. Key growth catalysts include increasing demand for diagnostic solutions in emerging markets and continued innovation in its product offerings. The company's strong gross margin of 56.7% and return on equity of 9.5% further support its value proposition. However, investors may want to evaluate the company's debt-to-equity ratio of 11.24% and the competitive landscape within the diagnostics industry. The absence of a dividend yield may also influence investment decisions.
Based on FMP financials and quantitative analysis
BMXMF Key Highlights
Market capitalization of $10.2B, reflecting its significant presence in the in vitro diagnostics market.
- Profit margin of 9.8%, indicating efficient profitability in its operations.
- Gross margin of 56.7%, showcasing strong pricing power and cost management.
- Return on Equity (ROE) of 9.5%, demonstrating effective utilization of shareholder equity.
- Debt-to-Equity ratio of 11.24%, indicating a moderate level of financial leverage.
Who Are BMXMF's Competitors?
BMXMF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| TMO Thermo Fisher Scientific Inc. | $603.18 | -0.41% | $224B | 645-pillar |
| DHR Danaher Corporation | $200.58 | -2.08% | $141B | 655-pillar |
| QGEN Qiagen N.V. | $42.13 | -0.87% | $8.69B | 835-pillar |
| ICLR ICON Public Limited Company | $165.69 | +3.87% | $12.7B | 705-pillar |
| TWST Twist Bioscience Corporation | $126.90 | +0.04% | $7.90B | 355-pillar |
| CRL Charles River Laboratories International, Inc. | $277.34 | +1.59% | $13.4B | 615-pillar |
| RVTY Revvity, Inc. | $120.94 | -2.35% | $13.5B | 665-pillar |
| MEDP Medpace Holdings, Inc. | $583.16 | -0.54% | $16.3B | 925-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are BMXMF's Key Strengths?
Strong market position in in vitro diagnostics.
- Diverse product portfolio.
- Global presence.
- Established customer relationships.
What Are BMXMF's Weaknesses?
Dependence on regulatory approvals.
- Exposure to currency fluctuations.
- Competition from larger players.
- Limited dividend yield.
What Could Drive BMXMF Stock Higher?
Potential for increased demand for diagnostic solutions due to emerging infectious disease outbreaks.
- Continued innovation in molecular diagnostics and personalized medicine.
- Expansion of product portfolio through strategic acquisitions.
- Growth in emerging markets with increasing healthcare expenditure.
- Potential regulatory approvals for new diagnostic platforms.
What Are the Key Risks for BMXMF?
Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
- Intense competition from larger players in the diagnostics industry.
- Dependence on regulatory approvals for new products.
- Exposure to currency fluctuations.
- Technological obsolescence.
- Economic downturns affecting healthcare spending.
What Are the Growth Opportunities for BMXMF?
- Expansion in Emerging Markets: bioMérieux can leverage the increasing healthcare expenditure in emerging markets such as China and India. These regions face a growing burden of infectious diseases and require advanced diagnostic solutions. By establishing strategic partnerships and expanding its distribution network, bioMérieux can capture a significant share of these markets. The emerging markets diagnostics market is projected to grow at a CAGR of 8-10% over the next five years.
- Innovation in Molecular Diagnostics: Investing in research and development to create innovative molecular diagnostic solutions can drive growth. Molecular diagnostics offer rapid and accurate detection of infectious diseases, genetic disorders, and cancers. bioMérieux can focus on developing new assays and platforms for personalized medicine, catering to the growing demand for targeted therapies. The global molecular diagnostics market is expected to reach $15 billion by 2028.
- Strategic Acquisitions: Pursuing strategic acquisitions of smaller diagnostic companies with complementary technologies can enhance bioMérieux's product portfolio and market reach. Acquisitions can provide access to new markets, innovative technologies, and specialized expertise. By integrating acquired companies effectively, bioMérieux can strengthen its competitive position and accelerate growth. The diagnostics industry is ripe for consolidation, offering numerous acquisition opportunities.
- Development of Point-of-Care Testing Solutions: Focusing on the development and commercialization of point-of-care testing (POCT) solutions can address the growing demand for rapid and convenient diagnostics. POCT devices enable testing at or near the patient's location, reducing turnaround time and improving patient outcomes. bioMérieux can develop POCT solutions for infectious diseases, cardiac markers, and other critical parameters. The global POCT market is projected to reach $40 billion by 2027.
- Partnerships with Pharmaceutical Companies: Collaborating with pharmaceutical companies to develop companion diagnostics can drive growth and enhance bioMérieux's value proposition. Companion diagnostics are used to identify patients who are most likely to benefit from a specific drug, enabling personalized treatment strategies. By partnering with pharmaceutical companies, bioMérieux can gain access to new markets and generate revenue from companion diagnostic assays. The companion diagnostics market is expected to grow significantly in the coming years, driven by the increasing adoption of targeted therapies.
What Are BMXMF's Competitive Advantages?
- Strong brand reputation in the diagnostics industry.
- Extensive product portfolio covering various diagnostic areas.
- Global presence with operations in multiple countries.
- Established relationships with key customers in the healthcare sector.
What Does BMXMF Do?
Founded in 1963 and headquartered in Marcy l'Etoile, France, bioMérieux S.A. has evolved into a global leader in the field of in vitro diagnostics. Originally known as B-D Mérieux, the company develops and produces diagnostic solutions aimed at identifying infectious diseases, cardiovascular pathologies, and various cancers. These solutions are crucial for clinical and hospital laboratories, physicians, blood banks, and industrial control laboratories. bioMérieux's offerings include diagnostic systems that analyze biological samples, as well as microbiological testing services primarily for the food, pharmaceutical, cosmetics, and veterinary sectors. The company's geographic reach spans the Americas, Europe, the Middle East, Africa, and the Asia Pacific, reflecting its commitment to global healthcare improvement. As a subsidiary of Institut Mérieux SA, bioMérieux continues to innovate and expand its diagnostic capabilities, addressing critical healthcare needs worldwide.
What Products and Services Does BMXMF Offer?
- Develops in vitro diagnostic solutions for infectious diseases.
- Produces diagnostic systems for cardiovascular pathologies.
- Offers diagnostic solutions for various cancers.
- Provides microbiological testing for the food industry.
- Offers microbiological testing for the pharmaceutical sector.
- Provides microbiological testing for the cosmetics industry.
- Offers microbiological testing for the veterinary sector.
How Does BMXMF Make Money?
- Develops and manufactures in vitro diagnostic systems.
- Sells diagnostic reagents and consumables.
- Provides microbiological testing services.
- Generates revenue through direct sales and distribution networks.
What Industry Does BMXMF Operate In?
bioMérieux S.A. operates within the growing in vitro diagnostics market, driven by increasing healthcare expenditure and the rising prevalence of infectious diseases. The industry is characterized by technological advancements, stringent regulatory requirements, and intense competition. Key players focus on developing innovative diagnostic solutions for personalized medicine and point-of-care testing. bioMérieux's established presence and diverse product portfolio position it well to capitalize on these trends.
Who Are BMXMF's Key Customers?
- Clinical and hospital laboratories.
- Physicians.
- Blood banks.
- Industrial control laboratories.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● No filing on record
- ● No analyst coverage
MoonshotScore History
Recorded daily since 2026-08-23 · 19 snapshots
| 2026-08-23 | 52 |
| 2026-08-26 | 52 |
| 2026-08-29 | 52 |
| 2026-09-01 | 52 |
| 2026-09-04 | 52 |
| 2026-09-07 | 52 |
| 2026-09-10 | 52 |
What changed?
The score has stayed at 52.
Over the same 18 days the stock moved +3.5%.
Company Profile
bioMérieux S.A. operates in the Diagnostics & Research industry within the Healthcare sector. It is headquartered in Marcy-l'Étoile, France.
How bioMérieux S.A. Is Valued
bioMérieux S.A. carries a market capitalization of $10.2B, placing it in the large-cap category.
Key Financial Metrics
Return on equity for bioMérieux S.A. stands at 9.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 7.1%, showing how much profit it generates from its asset base. BMXMF trades at a trailing price-to-earnings ratio of 18.16, below the Healthcare sector average of ~21.50x. Its free cash flow yield is 5.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.39 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 5.0%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
bioMérieux S.A.'s Piotroski F-Score is 8/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 6.22 places it in the safe zone, indicating low near-term bankruptcy risk.
Earnings Track Record
bioMérieux S.A. has missed Wall Street's EPS estimate in 5 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 7.3% above estimates on average.
Forward Outlook
Wall Street analysts project bioMérieux S.A. revenue of about $4.09B for fiscal 2026, with EPS near $4.31. The estimate reflects 7 contributing analysts.
BMXMF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Strong market position in in vitro diagnostics.
- Diverse product portfolio.
- Global presence.
- Established customer relationships.
Bear Case
- Dependence on regulatory approvals.
- Exposure to currency fluctuations.
- Competition from larger players.
- Limited dividend yield.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
BMXMF Latest News
-
BioMerieux SA (BMXMF) (Q2 2026) Earnings Call Highlights: Strong Cash Flow and Strategic ...
GuruFocus.com · Jul 28, 2026
-
Stocks That Hit 52-Week Highs On Tuesday
· Mar 24, 2020
-
Stocks That Hit 52-Week Highs On Tuesday
· Feb 4, 2020
-
Stocks That Hit 52-Week Highs On Tuesday
· Jan 21, 2020
BMXMF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for BMXMF.
Price Targets
Wall Street price target analysis for BMXMF.
BMXMF MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for BMXMF; grades run from A+ (80-100) to F (below 30).
Latest News
Leadership: Pierre Boulud
CEO
Pierre Boulud serves as the CEO of bioMérieux S.A., leading a global workforce of over 14,000 employees. His career spans several decades in the healthcare and diagnostics industries. Prior to joining bioMérieux, Boulud held various leadership positions at leading pharmaceutical and medical device companies. He brings extensive experience in strategic planning, operational management, and business development. Boulud's expertise lies in driving innovation and expanding market presence in the healthcare sector.
Track Record: Under Pierre Boulud's leadership, bioMérieux S.A. has focused on expanding its global footprint and investing in innovative diagnostic solutions. Key achievements include the successful launch of new diagnostic platforms and the expansion of the company's presence in emerging markets. Boulud has also overseen strategic acquisitions and partnerships to enhance bioMérieux's product portfolio and market reach. His focus on innovation and operational excellence has contributed to the company's growth and profitability.
BMXMF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that bioMérieux S.A. (BMXMF) may not meet the listing requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited financial disclosure and may not be subject to the same regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. Investing in OTC Other stocks carries significant risks due to the potential for limited information and liquidity.
- OTC Tier: OTC Other
- Limited financial disclosure increases the risk of investing in BMXMF.
- Low trading volume can lead to price volatility and difficulty in exiting positions.
- The OTC Other tier carries a higher risk of fraud and manipulation.
- Lack of regulatory oversight may expose investors to greater risks.
- The company may not meet the listing requirements of higher-tier exchanges.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's growth prospects and potential risks.
- Check for any regulatory actions or legal issues.
- Monitor trading volume and price volatility.
- Consult with a financial advisor before investing.
- bioMérieux S.A. is a subsidiary of Institut Mérieux SA, a reputable holding company.
- The company has a long operating history, founded in 1963.
- bioMérieux S.A. has a global presence and serves various sectors.
- The company develops and produces in vitro diagnostic solutions.
- The company has over 14,000 employees.
BMXMF Healthcare Stock FAQ
Is BMXMF a good stock?
Stock Expert AI does not rate BMXMF buy, sell or hold. bioMérieux S.A. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What do analysts say about BMXMF stock?
Analyst coverage of BMXMF is limited due to its OTC listing. However, considering bioMérieux S.A.'s financial performance and market position, analysts generally view the company as a stable player in the in vitro diagnostics market. Key valuation metrics include its market capitalization of $10.2B, profit margin of 9.8%, and gross margin of 56.7%.
What are the key factors to evaluate for BMXMF?
Evaluate BMXMF on fundamentals, analyst consensus, and risk factors. P/E: 18.16x vs the S&P 500's ~20-25x. The company's strong gross margin of 56.7% and return on equity of 9.5% further support its value proposition. Not financial advice.
How frequently does BMXMF data refresh on this page?
BMXMF's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven BMXMF's recent stock price performance?
bioMérieux S.A. (BMXMF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong market position in in vitro diagnostics. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider BMXMF overvalued or undervalued right now?
bioMérieux S.A. (BMXMF) trades at 18.16x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of BMXMF?
Yes, most major brokerages offer fractional shares of bioMérieux S.A. (BMXMF) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track BMXMF's earnings and financial reports?
bioMérieux S.A. (BMXMF) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for BMXMF earnings announcements.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on available information and may be subject to change.
- OTC market data may be limited and less reliable than data from major exchanges.